Journal of Clinical Endocrinology & Metabolism, Vol 77, 790-793, Copyright © 1993 by Endocrine Society

ARTICLES

Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly

B Merola, A Cittadini, A Colao, D Ferone, S Fazio, D Sabatini, B Biondi, L Sacca and G Lombardi
Cattedra di Endocrinologia e Istituto di Medicina Interna, II Facolta di Medicina e Chirurgia, Universita di Napoli, Italy.

The aim of this study was to investigate the effects of a 6-month octreotide treatment on cardiac mass and function by means of Doppler echocardiography in 11 normotensive patients affected with active acromegaly. The GH and insulin-like growth factor-I levels were normalized during octreotide therapy from 34 +/- 6.5 and 767.4 +/- 72.4 micrograms/L to 4.6 +/- 0.9 and 235 +/- 10.3 micrograms/L, respectively (P < 0.001; mean +/- SEM). After the 6-month treatment, we observed a significant decrease in the left ventricular mass index from 138 +/- 11 to 116 +/- 13 g/m2 (P < 0.001) and in the mean wall thickness/internal end-diastolic radius ratio from 0.47 +/- 0.1 to 0.44 +/- 0.1 (P < 0.001). No significant differences were found in systolic function indices, whereas diastolic filling indices improved over the course of the therapy; the isovolumic relaxation time decreased from 115 +/- 6 to 100 +/- 6 ms (P < 0.05), tricuspid late diastolic filling velocities decreased from 41 +/- 3 to 36 +/- 2 cm/s (P < 0.03), and tricuspid deceleration time decreased from 280 +/- 28 to 198 +/- 15 ms (P < 0.005); the ratio of early to late peak velocity of the right ventricular filling significantly increased from 1 +/- 0.01 to 1.3 +/- 0.1 (P < 0.03). A significant correlation was detected between left ventricular mass regression and increase in the early to late peak velocity ratio of the left ventricular filling (r = 0.62; P < 0.05). The results of this study show an improvement in cardiac structural and functional abnormalities during chronic treatment with octreotide, thus supporting the hypothesis of a specific heart disease secondary to high circulating GH levels.

This article has been cited by other articles:

				H. Gouya, O. Vignaux, P. Le Roux, P. Chanson, J. Bertherat, X. Bertagna, and P. Legmann Rapidly Reversible Myocardial Edema in Patients with Acromegaly: Assessment with Ultrafast T2 Mapping in a Single-Breath-Hold MRI Sequence Am. J. Roentgenol., June 1, 2008; 190(6): 1576 - 1582. [Abstract] [Full Text] [PDF]

				F. Bogazzi, L. Battolla, C. Spinelli, G. Rossi, S. Gavioli, V. Di Bello, C. Cosci, C. Sardella, D. Volterrani, E. Talini, et al. Risk Factors for Development of Coronary Heart Disease in Patients with Acromegaly: A Five-Year Prospective Study J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4271 - 4277. [Abstract] [Full Text] [PDF]

				P. Maison, A.-I. Tropeano, I. Macquin-Mavier, A. Giustina, and P. Chanson Impact of Somatostatin Analogs on the Heart in Acromegaly: A Metaanalysis J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1743 - 1747. [Abstract] [Full Text] [PDF]

				E. R. Schwarz, P. Jammula, R. Gupta, and S. Rosanio A Case and Review of Acromegaly-Induced Cardiomyopathy and the Relationship Between Growth Hormone and Heart Failure: Cause or Cure or Neither or Both? Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2006; 11(4): 232 - 244. [Abstract] [PDF]

				W. H T Smith, R U. Nair, D. Adamson, M. T Kearney, S. G Ball, and A. J Balmforth Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts J. Endocrinol., December 1, 2005; 187(3): 379 - 386. [Abstract] [Full Text] [PDF]

				S W van Thiel, J J Bax, N R Biermasz, E R Holman, D Poldermans, F Roelfsema, H J Lamb, E E van der Wall, J W A Smit, J A Romijn, et al. Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly Eur. J. Endocrinol., August 1, 2005; 153(2): 231 - 238. [Abstract] [Full Text] [PDF]

				H. Bihan, C. Espinosa, H. Valdes-Socin, S. Salenave, J. Young, S. Levasseur, P. Assayag, A. Beckers, and P. Chanson Long-Term Outcome of Patients with Acromegaly and Congestive Heart Failure J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5308 - 5313. [Abstract] [Full Text] [PDF]

				A. Colao, D. Ferone, P. Marzullo, and G. Lombardi Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management Endocr. Rev., February 1, 2004; 25(1): 102 - 152. [Abstract] [Full Text] [PDF]

				J. C. Smith, H. Lane, N. Davies, L. M. Evans, J. Cockcroft, M. F. Scanlon, and J. S. Davies The Effects of Depot Long-Acting Somatostatin Analog on Central Aortic Pressure and Arterial Stiffness in Acromegaly J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2556 - 2561. [Abstract] [Full Text] [PDF]

				P. U. Freda Somatostatin Analogs in Acromegaly J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3013 - 3018. [Full Text] [PDF]

				A. Cittadini, A. Berggren, S. Longobardi, C. Ehrnborg, R. Napoli, T. Rosen, S. Fazio, K. Caidahl, B.-A. Bengtsson, and L. Sacca Supraphysiological Doses of GH Induce Rapid Changes in Cardiac Morphology and Function J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1654 - 1659. [Abstract] [Full Text] [PDF]

				A. Colao, A. Cuocolo, P. Marzullo, E. Nicolai, D. Ferone, A. M. Della Morte, R. Pivonello, M. Salvatore, and G. Lombardi Is the Acromegalic Cardiomyopathy Reversible? Effect of 5-Year Normalization of Growth Hormone and Insulin-Like Growth Factor I Levels on Cardiac Performance J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1551 - 1557. [Abstract] [Full Text]

				L Friberg, S Werner, G Eggertsen, and S Ahnve Growth hormone and insulin-like growth factor-1 in acute myocardial infarction Eur. Heart J., September 2, 2000; 21(18): 1547 - 1554. [Abstract] [PDF]

				A. Colao, P. Marzullo, D. Ferone, L. Spinelli, A. Cuocolo, D. Bonaduce, M. Salvatore, V. Boerlin, I. Lancranjan, and G. Lombardi Cardiovascular Effects of Depot Long-Acting Somatostatin Analog Sandostatin LAR in Acromegaly J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3132 - 3140. [Abstract] [Full Text]

				A. Colao, R. Baldelli, P. Marzullo, E. Ferretti, D. Ferone, P. Gargiulo, M. Petretta, G. Tamburrano, G. Lombardi, and A. Liuzzi Systemic Hypertension and Impaired Glucose Tolerance Are Independently Correlated to the Severity of the Acromegalic Cardiomyopathy J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 193 - 199. [Abstract] [Full Text]

				A. Colao, A. Cuocolo, P. Marzullo, E. Nicolai, D. Ferone, A. M. D. Morte, M. Petretta, M. Salvatore, and G. Lombardi Impact of Patient's Age and Disease Duration on Cardiac Performance in Acromegaly: A Radionuclide Angiography Study J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1518 - 1523. [Abstract] [Full Text]

				R. Baldelli, E. Ferretti, M.-L. Jaffrain-Rea, G. Iacobellis, G. Minniti, B. Caracciolo, C. Moroni, R. Cassone, A. Gulino, and G. Tamburrano Cardiac Effects of Slow-Release Lanreotide, a Slow-Release Somatostatin Analog, in Acromegalic Patients J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 527 - 532. [Abstract] [Full Text]

				A. Colao, A. Cuocolo, P. Marzullo, E. Nicolai, D. Ferone, L. Florimonte, M. Salvatore, and G. Lombardi Effects of 1-Year Treatment with Octreotide on Cardiac Performance in Patients with Acromegaly J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 17 - 23. [Abstract] [Full Text]

				A. Cittadini, H. Stromer, D. E. Vatner, J. D. Grossman, S. E. Katz, R. Clark, J. P. Morgan, and P. S. Douglas Consequences of Growth Hormone Deficiency on Cardiac Structure, Function, and {beta}-Adrenergic Pathway: Studies in Mutant Dwarf Rats Endocrinology, December 1, 1997; 138(12): 5161 - 5169. [Abstract] [Full Text] [PDF]

				A. Colao, D. Ferone, P. Cappabianca, M. L. del Basso De Caro, P. Marzullo, A. Monticelli, A. Alfieri, B. Merola, A. CalI, E. de Divitiis, et al. Effect of Octreotide Pretreatment on Surgical Outcome in Acromegaly J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3308 - 3314. [Abstract] [Full Text] [PDF]

				L. Sacca Growth hormone: a newcomer in cardiovascular medicine Cardiovasc Res, October 1, 1997; 36(1): 3 - 9. [Full Text] [PDF]

				A. Colao, B. Merola, D. Ferone, and G. Lombardi Acromegaly J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2777 - 2781. [Full Text] [PDF]

				R. Lopez-Velasco, H. F. Escobar-Morreale, B. Vega, E. Villa, J. M. Sancho, J. L. Moya-Mur, and R. Garcia-Robles Cardiac Involvement in Acromegaly: Specific Myocardiopathy or Consequence of Systemic Hypertension? J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1047 - 1053. [Abstract] [Full Text] [PDF]

				A. Cittadini, H. Stromer, S. E. Katz, R. Clark, A. C. Moses, J. P. Morgan, and P. S. Douglas Differential Cardiac Effects of Growth Hormone and Insulin-like Growth Factor1 in the Rat : A Combined In Vivo and In Vitro Evaluation Circulation, February 15, 1996; 93(4): 800 - 809. [Abstract] [Full Text]